D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 94 Citations 45,343 511 World Ranking 5002 National Ranking 138

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Chemotherapy

His primary areas of study are Multiple myeloma, Internal medicine, Surgery, Oncology and Bortezomib. His studies deal with areas such as Chemotherapy, Dexamethasone and Transplantation as well as Multiple myeloma. His Transplantation research focuses on subjects like Clinical endpoint, which are linked to Hazard ratio.

His studies examine the connections between Internal medicine and genetics, as well as such issues in Gastroenterology, with regards to Beta-2 microglobulin. While the research belongs to areas of Surgery, Thierry Facon spends his time largely on the problem of Urology, intersecting his research to questions surrounding Induction chemotherapy. His biological study spans a wide range of topics, including Clinical trial, Pathology, Immunology, Very Good Partial Response and Survival analysis.

His most cited work include:

  • A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma (2415 citations)
  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma (2128 citations)
  • Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma (1211 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Multiple myeloma, Internal medicine, Oncology, Surgery and Lenalidomide. His Multiple myeloma study incorporates themes from Newly diagnosed, Transplantation and Dexamethasone. His research in Internal medicine intersects with topics in Gastroenterology and Immunology.

His Oncology study also includes

  • Cytogenetics which connect with Bone marrow,
  • Fluorescence in situ hybridization most often made with reference to Pathology. As part of his studies on Surgery, Thierry Facon often connects relevant subjects like Urology. His Lenalidomide study combines topics from a wide range of disciplines, such as Pediatrics, Neutropenia, Pharmacology and Phases of clinical research.

He most often published in these fields:

  • Multiple myeloma (73.06%)
  • Internal medicine (64.92%)
  • Oncology (32.55%)

What were the highlights of his more recent work (between 2016-2021)?

  • Multiple myeloma (73.06%)
  • Internal medicine (64.92%)
  • Oncology (32.55%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Multiple myeloma, Internal medicine, Oncology, Dexamethasone and Lenalidomide. Thierry Facon has included themes like Newly diagnosed, Adverse effect and Transplantation in his Multiple myeloma study. His work in Internal medicine is not limited to one particular discipline; it also encompasses Gastroenterology.

In his study, Clinical trial is strongly linked to Randomized controlled trial, which falls under the umbrella field of Dexamethasone. His Lenalidomide research incorporates elements of Thalidomide, Survival rate, Surgery, Phases of clinical research and Clinical endpoint. His Bortezomib research includes themes of Proteasome inhibitor and Autologous stem-cell transplantation.

Between 2016 and 2021, his most popular works were:

  • Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study (261 citations)
  • Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial (180 citations)
  • Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM (145 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Chemotherapy

His main research concerns Multiple myeloma, Internal medicine, Lenalidomide, Oncology and Bortezomib. His Multiple myeloma study incorporates themes from Interim analysis, Clinical trial, MEDLINE, Adverse effect and Transplantation. His Internal medicine study often links to related topics such as Gastroenterology.

Thierry Facon interconnects Survival rate, Clinical endpoint, Thalidomide and Pembrolizumab in the investigation of issues within Lenalidomide. The concepts of his Thalidomide study are interwoven with issues in Autologous stem-cell transplantation and Melphalan. His studies deal with areas such as Prospective cohort study and Surgery as well as Bortezomib.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

Michel Attal;Jean-Luc Harousseau;Anne-Marie Stoppa;Jean-Jacques Sotto.
The New England Journal of Medicine (1996)

4029 Citations

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin.
The New England Journal of Medicine (2005)

2881 Citations

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Meletios Dimopoulos;Andrew Spencer;Michael Attal;H. Miles Prince.
The New England Journal of Medicine (2007)

1802 Citations

Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

Michel Attal;Jean-Luc Harousseau;Thierry Facon;François Guilhot.
The New England Journal of Medicine (2003)

1414 Citations

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.

Thierry Facon;Jean Yves Mary;Cyrille Hulin;Lotfi Benboubker.
The Lancet (2007)

1203 Citations

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome

Hervé Avet-Loiseau;Michel Attal;Philippe Moreau;Catherine Charbonnel.
Blood (2007)

1063 Citations

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

Michel Attal;Jean-Luc Harousseau;Serge Leyvraz;Chantal Doyen.
Blood (2006)

860 Citations

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

Andreas Hochhaus;Hagop M. Kantarjian;Michele Baccarani;Jeffrey H. Lipton.
Blood (2007)

786 Citations

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment

Catherine Roche-Lestienne;Valerie Soenen-Cornu;Nathalie Grardel-Duflos;Jean-Luc Laı̈.
Blood (2002)

758 Citations

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua.
Lancet Oncology (2016)

720 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Thierry Facon

Kenneth C. Anderson

Kenneth C. Anderson

Harvard University

Publications: 362

Paul G. Richardson

Paul G. Richardson

Harvard University

Publications: 357

Meletios A. Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens

Publications: 311

Shaji Kumar

Shaji Kumar

Mayo Clinic

Publications: 308

Morie A. Gertz

Morie A. Gertz

Mayo Clinic

Publications: 273

Angela Dispenzieri

Angela Dispenzieri

Mayo Clinic

Publications: 257

Nikhil C. Munshi

Nikhil C. Munshi

Harvard University

Publications: 250

Antonio Palumbo

Antonio Palumbo

University of Turin

Publications: 235

Philippe Moreau

Philippe Moreau

University of Nantes

Publications: 229

S. Vincent Rajkumar

S. Vincent Rajkumar

Mayo Clinic

Publications: 221

Robert A. Kyle

Robert A. Kyle

Mayo Clinic

Publications: 208

Martha Q. Lacy

Martha Q. Lacy

Mayo Clinic

Publications: 195

Pieter Sonneveld

Pieter Sonneveld

Erasmus University Rotterdam

Publications: 194

Evangelos Terpos

Evangelos Terpos

National and Kapodistrian University of Athens

Publications: 190

Sagar Lonial

Sagar Lonial

Emory University

Publications: 188

Gareth J. Morgan

Gareth J. Morgan

New York University

Publications: 185

Trending Scientists

Mohammad Hassan Khooban

Mohammad Hassan Khooban

Aarhus University

Valentin B. Fainerman

Valentin B. Fainerman

Max Planck Society

Mahendra Kumar Jain

Mahendra Kumar Jain

University of Delaware

Peter Hinterdorfer

Peter Hinterdorfer

Johannes Kepler University of Linz

Junying Zhang

Junying Zhang

Huazhong University of Science and Technology

A. D. Buckingham

A. D. Buckingham

University of Cambridge

Angie Rizzino

Angie Rizzino

University of Nebraska Medical Center

Douglas W. Schemske

Douglas W. Schemske

Michigan State University

Kalidas Shetty

Kalidas Shetty

North Dakota State University

Louis Lambrechts

Louis Lambrechts

Institut Pasteur

James M. Trout

James M. Trout

United States Department of Agriculture

Mikael Fortelius

Mikael Fortelius

University of Helsinki

Mario Rosanova

Mario Rosanova

University of Milan

Donald G. Rainnie

Donald G. Rainnie

Emory University

Odile Launay

Odile Launay

Université Paris Cité

David J. Greenblatt

David J. Greenblatt

Tufts University

Something went wrong. Please try again later.